You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

c-Met NSCLC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial (Telisotuzumab Vedotin, Osimertinib, Cisplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Telisotuzumab Vedotin
  • +4 more
  • (no location specified)
Oct 17, 2023

c-MET Expression and EGFR Gene Mutation Correlation With

Completed
  • Non-small Cell Lung Cancer Metastatic
  • Non-small Cell Lung Cancer Recurrent
    • Hwasun, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Aug 1, 2021

    NSCLC Trial in China (BPI-9016M)

    Recruiting
    • Non-small Cell Lung Cancer
    • Hefei, Anhui, China
    • +6 more
    Sep 5, 2021

    NSCLC Trial in Worldwide (Osimertinib + Savolitinib, Savolitinib + Placebo)

    Active, not recruiting
    • Non-Small Cell Lung Cancer
    • Osimertinib + Savolitinib
    • Savolitinib + Placebo
    • Duarte, California
    • +20 more
    Dec 2, 2022

    NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)

    Not yet recruiting
    • NSCLC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center of Sun-Yat Sen University
    Sep 19, 2023

    NSCLC Metastatic, Gastric Cancer, Head Neck Cancer Trial in Orange, West Valley City (MCLA-129)

    Recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • +2 more
    • Orange, California
    • +1 more
    May 21, 2021

    NSCLC Metastatic Trial in Seoul (Lazertinib, Tepotinib)

    Not yet recruiting
    • Non-Small Cell Lung Cancer Metastatic
    • Seoul, Gangnam-gu, Korea, Republic of
      Samsung Medical Center
    Oct 27, 2023

    NSCLC Trial in Houston (Amivantamab, Tepotinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 9, 2023

    NSCLC Trial in Guangzhou (Savolitinib, Docetaxel)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Department of Thoracic Surgery and Oncology, The First Affiliate
    Mar 17, 2023

    NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

    Not yet recruiting
    • Non-Small Cell Lung Cancer
    • HS-10241+ Almonertinib
    • Pemetrexed + Cisplatin /Carboplatin
    • (no location specified)
    Oct 29, 2023

    Tumors Trial (ABN401)

    Not yet recruiting
    • Neoplasms
    • (no location specified)
    May 21, 2023

    Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)

    Not yet recruiting
    • Advanced Cancer
    • Non Small Cell Lung Cancer
    • (no location specified)
    Mar 28, 2023

    NSCLC Trial in Pittsburgh (Capmatinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Jan 9, 2023

    Lung Cancer Trial (Savolitinib, Durvalumab)

    Recruiting
    • Lung Cancer
    • Beijing, China
    • +2 more
    Jan 11, 2023

    Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)

    Recruiting
    • Non-Small Cell Lung Carcinoma
    • Capmatinib 150 mg
    • Capmatinib 200 mg
    • Guwahati, Assam, India
    • +7 more
    Dec 19, 2022

    Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain

    Completed
    • Metastatic Non-Small Cell Lung Cancer
    • East Hanover, New Jersey
      18 Novartis Investigative Sites in the US
    Dec 29, 2022

    Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))

    Completed
    Has Results
    • Malignant Non-small Cell Neoplasm of Lung Stage IV
    • Capmatinib (INC280)
    • Boston, Massachusetts
      Massachusetts General Hospital
    Mar 11, 2022

    NSCLC Trial in Guangzhou (PLB1001)

    Active, not recruiting
    • Non-small Cell Lung Cancer
    • Guangzhou, Guangdong, China
      Guangdong Provincial People's Hospital
    Aug 15, 2023

    Advanced NSCLC With MET Mutations Trial in United States (Tepotinib)

    Recruiting
    • Advanced Non-Small Cell Lung Cancer With MET Mutations
    • Aurora, Colorado
    • +3 more
    Jun 27, 2022

    NSCLC (NSCLC) Trial in China (Capmatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Xiamen, Fujian, China
    • +18 more
    Jan 27, 2023

    Non Small Cell Lung Cancer (NSCLC), Metastases to the Brain Trial in Pittsburgh (cabozantinib)

    Terminated
    Has Results
    • Non Small Cell Lung Cancer (NSCLC)
    • Metastases to the Brain
    • Pittsburgh, Pennsylvania
      University of Pittsburgh Cancer Institute- Hillman Cancer Center
    Mar 8, 2021

    Solid Tumor Trial in Bengbu (SPH 3348)

    Recruiting
    • Solid Tumor
    • SPH 3348
    • Bengbu, Anhui, China
      The First Affliated Hospital of Bengbu Medical College
    Jul 25, 2022

    Lung Non-Small Cell Carcinoma Trial (Amivantamab, Biospecimen Collection, Computed Tomography)

    Not yet recruiting
    • Lung Non-Small Cell Carcinoma
    • Amivantamab
    • +3 more
    • (no location specified)
    Oct 30, 2023

    NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)

    Recruiting
    • Non-Small Cell Lung Cancer
    • +5 more
    • Toripalimab
    • +3 more
    • Guanzhou, Guangdong, China
      Guangdong Lung Cancer Institute, Guangdong Provincial People's H
    Apr 4, 2023

    NSCLC Trial in United States (capmatinib)

    Recruiting
    • Non-small Cell Lung Cancer
    • La Jolla, California
    • +7 more
    Oct 5, 2022